Skip to main content
Premium Trial:

Request an Annual Quote

Bayer, OrigiMed Form Companion Diagnostic Development Alliance

NEW YORK — Bayer has partnered with OrigiMed on the development of a next-generation sequencing-based companion diagnostic for the cancer drug larotrectinib (Vitrakvi) for the Chinese market, the companies said on Wednesday.

Larotrectinib is a tropomyosin receptor kinase inhibitor approved in the US and Europe for the treatment of solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusions. Bayer acquired the exclusive rights to the drug from Loxo Oncology, now an Eli Lilly subsidiary,  last year.

Under the terms of their deal, Bayer and Shanghai-based OrigiMed will develop an in vitro diagnostic for mainland China to identify cancer patients with NTRK fusions who would benefit from larotrectinib treatment. The patients may also be enrolled in clinical trials for the drug in the nation.

Additional terms were not disclosed.

About a year ago, Leverkusen, Germany-based Bayer formed a companion diagnostic development alliance with Foundation Medicine, with an initial focus on a test for use with larotrectinib.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.